Teva launches Ajovy auto-injector device

Migraine patients now have the flexibility of quarterly or monthly dosing options of Ajovy (fremanezumab-vfrm) injection.

Teva is introducing its auto-injector device for Ajovy (fremanezumab-vfrm) injection, which the Food and Drug Administration approved in January. 

Ajovy is the only long-acting anti-CGRP injection with the option of dosing four times per year, using either the auto-injector or prefilled syringe. The new Teva auto-injector also has several features that makes it easy to use, including a button-free, push-down mechanism; audible cues that signal progress of administration; and a window that displays when the dose has been delivered. Additionally, the auto-injector is for one-time use only and locks after use.

The wholesale acquisition cost or list price for the Ajovy auto-injector is $603.20. Actual costs to individual patients and providers for the auto-injector are anticipated to be lower than WAC because WAC does not account for additional rebates and discounts that may apply. Savings on out-of-pocket costs may vary depending on the patient’s insurance payer and eligibility for participation in the assistance program.